RS63848B1 - Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina - Google Patents

Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina

Info

Publication number
RS63848B1
RS63848B1 RS20221174A RSP20221174A RS63848B1 RS 63848 B1 RS63848 B1 RS 63848B1 RS 20221174 A RS20221174 A RS 20221174A RS P20221174 A RSP20221174 A RS P20221174A RS 63848 B1 RS63848 B1 RS 63848B1
Authority
RS
Serbia
Prior art keywords
acid
compound
lipid
solution
filtered
Prior art date
Application number
RS20221174A
Other languages
English (en)
Serbian (sr)
Inventor
Steven M Ansell
Xinyao Du
Original Assignee
Acuitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acuitas Therapeutics Inc filed Critical Acuitas Therapeutics Inc
Publication of RS63848B1 publication Critical patent/RS63848B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/10—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of a carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33306—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RS20221174A 2014-06-25 2015-06-05 Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina RS63848B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016839P 2014-06-25 2014-06-25
EP20195502.8A EP3766916B1 (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Publications (1)

Publication Number Publication Date
RS63848B1 true RS63848B1 (sr) 2023-01-31

Family

ID=53433312

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20221174A RS63848B1 (sr) 2014-06-25 2015-06-05 Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina

Country Status (17)

Country Link
US (6) US9738593B2 (enExample)
EP (3) EP4148083A1 (enExample)
JP (5) JP6594421B2 (enExample)
CN (2) CN111454165B (enExample)
AU (4) AU2015280499B2 (enExample)
CA (2) CA2953341C (enExample)
ES (2) ES2931832T3 (enExample)
HR (1) HRP20221536T1 (enExample)
HU (1) HUE060907T2 (enExample)
IL (6) IL289934B2 (enExample)
LT (1) LT3766916T (enExample)
PL (1) PL3766916T3 (enExample)
PT (1) PT3766916T (enExample)
RS (1) RS63848B1 (enExample)
SI (1) SI3766916T1 (enExample)
SM (1) SMT202200502T1 (enExample)
WO (1) WO2015199952A1 (enExample)

Families Citing this family (572)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
ES3032013T3 (en) 2013-03-15 2025-07-14 Translate Bio Inc Synergistic enhancement of the delivery of nucleic acids via blended formulations
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN114085198A (zh) 2015-06-29 2022-02-25 爱康泰生治疗公司 用于递送核酸的脂质和脂质纳米颗粒制剂
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
JP7064214B2 (ja) 2015-09-28 2022-05-10 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗体回避性ウイルスベクターのための方法および組成物
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
RS63986B1 (sr) * 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
WO2017106799A1 (en) * 2015-12-17 2017-06-22 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US10457631B2 (en) 2016-04-06 2019-10-29 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
CN109072223B (zh) 2016-04-08 2022-10-21 川斯勒佰尔公司 多聚体编码核酸及其用途
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
CN109152735B (zh) 2016-05-09 2022-03-11 阿斯利康(瑞典)有限公司 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
US20200085916A1 (en) 2016-05-18 2020-03-19 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
EP3458106A4 (en) * 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
EP3458108A4 (en) * 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3458081A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
CA3024507A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
EP3458083B1 (en) 2016-05-18 2022-11-02 ModernaTX, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
ES2973443T3 (es) 2016-05-18 2024-06-20 Modernatx Inc Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
EP3469074B1 (en) 2016-06-13 2020-12-09 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
US20200069599A1 (en) 2016-06-14 2020-03-05 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
IL317855A (en) * 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
EP4714454A2 (en) 2016-10-26 2026-03-25 Acuitas Therapeutics Inc. Lipid nanoparticle formulations
US20190274968A1 (en) 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
PT3538515T (pt) 2016-11-08 2022-09-30 Univ Ramot Composto de pirimidina como inibidor de jak cinase
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
AU2017374042C1 (en) * 2016-12-09 2024-07-11 Acuitas Therapeutics, Inc. Delivery of target specific nucleases
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
US11241490B2 (en) 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018157009A1 (en) * 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
FI3596041T3 (fi) * 2017-03-15 2023-01-31 Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170260A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
JP2020514370A (ja) 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
WO2019012336A2 (en) 2017-03-17 2019-01-17 Newcastle University ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
KR102842382B1 (ko) 2017-03-24 2025-08-04 큐어백 에스이 Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018191719A1 (en) * 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3618859A4 (en) 2017-04-27 2021-05-05 Vanderbilt University HEPATITIS C VIRUS SEQUENCES AND METHODS OF USING THEREFORE
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3641834B1 (en) 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
WO2019126593A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
CN118512596A (zh) 2017-12-27 2024-08-20 武田药品工业株式会社 含核酸脂质纳米粒子及其用途
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019152557A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
MX2020010464A (es) 2018-04-03 2021-01-29 Vectores de virus que evitan anticuerpos.
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
JP7425738B2 (ja) 2018-04-03 2024-01-31 ギンコ バイオワークス インコーポレイテッド 眼組織を標的とするウイルスベクター
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
SG11202008225PA (en) * 2018-04-17 2020-11-27 Curevac Ag Novel rsv rna molecules and compositions for vaccination
EP3793689A1 (en) 2018-05-15 2021-03-24 Translate Bio, Inc. Subcutaneous delivery of messenger rna
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
CA3100254A1 (en) 2018-05-24 2019-11-28 Translate Bio, Inc. Thioester cationic lipids
CA3100214A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
JP7441802B2 (ja) 2018-05-30 2024-03-01 トランスレイト バイオ， インコーポレイテッド ビタミンカチオン性脂質
WO2019232097A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
US20200016274A1 (en) 2018-05-30 2020-01-16 Translate Bio, Inc. Messenger rna vaccines and uses thereof
PL3805198T3 (pl) 2018-06-08 2024-02-12 Fujifilm Corporation Związek, jego sól i cząstki lipidowe
EP4591888A3 (en) 2018-06-18 2026-01-21 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
US12109310B2 (en) 2018-06-28 2024-10-08 Hadi Valadi Exosome extracellular vesicles and methods of use
WO2020023533A1 (en) 2018-07-23 2020-01-30 Translate Bio, Inc. Dry power formulations for messenger rna
CN111164068B (zh) * 2018-08-21 2023-11-14 株式会社东芝 生物降解性化合物、脂质粒子、含有脂质粒子的组合物、及试剂盒
AU2019333042B2 (en) 2018-08-29 2025-06-19 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
WO2020056304A1 (en) 2018-09-14 2020-03-19 Modernatx, Inc. Methods and compositions for treating cancer using mrna therapeutics
EP3849617A1 (en) 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
EP3853202A1 (en) * 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP4613367A1 (en) 2018-09-21 2025-09-10 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
CN112912509B (zh) 2018-10-18 2024-12-31 武田药品工业株式会社 T细胞的活化/增殖方法
AU2019361129A1 (en) 2018-10-18 2021-05-20 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN112888451A (zh) 2018-10-19 2021-06-01 川斯勒佰尔公司 信使rna的无泵包封
US12280147B2 (en) 2018-11-09 2025-04-22 Translate Bio, Inc. PEG lipidoid compounds
JP7483294B2 (ja) 2018-11-09 2024-05-15 トランスレイト バイオ， インコーポレイテッド 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
US20220016265A1 (en) 2018-11-09 2022-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
AU2019377525B2 (en) 2018-11-09 2025-10-16 Translate Bio, Inc. Multi-PEG lipid compounds
CA3119449A1 (en) 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
US12257305B2 (en) 2018-11-21 2025-03-25 Translate Bio, Inc. Cationic lipid compounds
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
JP2022516356A (ja) 2019-01-07 2022-02-25 トランスレイト バイオ， インコーポレイテッド 原発性線毛機能不全症の治療のための組成物および方法
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
JP7698583B2 (ja) 2019-03-21 2025-06-25 ギンコ バイオワークス インコーポレイテッド 組換えアデノ随伴ウイルスベクター
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
US20220233444A1 (en) 2019-04-22 2022-07-28 Translate Bio, Inc. Thioester cationic lipids
AU2020261419B2 (en) * 2019-04-25 2026-01-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
EP3962902A1 (en) 2019-05-03 2022-03-09 Translate Bio, Inc. Di-thioester cationic lipids
JP2022531461A (ja) 2019-05-07 2022-07-06 モデルナティエックス インコーポレイテッド 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法
WO2020227537A1 (en) 2019-05-07 2020-11-12 Modernatx, Inc Differentially expressed immune cell micrornas for regulation of protein expression
EP3976593A1 (en) 2019-05-31 2022-04-06 Translate Bio, Inc. Macrocyclic lipids
CN114375334B (zh) 2019-06-07 2026-03-20 斯克里贝治疗公司 工程化CasX系统
EP3981435B1 (en) 2019-06-07 2023-08-16 FUJIFILM Corporation Lipid composition
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
CN114401942B (zh) 2019-06-21 2024-01-26 川斯勒佰尔公司 三(羟甲基)甲基甘氨酸和柠檬酸脂质
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
JP7586886B2 (ja) 2019-07-08 2024-11-19 トランスレイト バイオ， インコーポレイテッド 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス
CN114423869A (zh) 2019-07-19 2022-04-29 旗舰先锋创新Vi有限责任公司 重组酶组合物和使用方法
US12144871B2 (en) 2019-07-23 2024-11-19 Translate Bio, Inc. Stable compositions of MRNA-loaded lipid nanoparticles and processes of making
EP4003296A1 (en) * 2019-07-31 2022-06-01 ModernaTX, Inc. Compositions and methods for delivery of rna interference agents to immune cells
EP4009955A1 (en) 2019-08-07 2022-06-15 ModernaTX, Inc. Compositions and methods for enhanced delivery of agents
GEP20257820B (en) * 2019-08-14 2025-11-10 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids
JP2022544412A (ja) 2019-08-14 2022-10-18 キュアバック アーゲー 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物
JP7700101B2 (ja) 2019-09-06 2025-06-30 ジェネレーション バイオ カンパニー 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
BR112022004936A2 (pt) * 2019-09-19 2022-06-14 Modernatx Inc Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
US20240197825A1 (en) 2019-09-20 2024-06-20 Translate Bio, Inc. mRNA Encoding Engineered CFTR
CA3147643A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
EP4048807A1 (en) 2019-09-23 2022-08-31 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein b (apob) gene expression
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
IL292297A (en) 2019-10-17 2022-06-01 Stridebio Inc Adeno-associated viral vectors for treatment of niemann-pick disease type c
WO2021081058A1 (en) 2019-10-21 2021-04-29 Translate Bio, Inc. Compositions, methods and uses of messenger rna
EP4328309B1 (en) * 2019-11-15 2025-07-02 FUJIFILM Corporation Lipid composition
CA3154774A1 (en) 2019-11-22 2021-05-27 Generation Bio Co. Ionizable lipids and nanoparticle compositions thereof
IL294073A (en) 2019-12-20 2022-08-01 Translate Bio Inc Rectal administration of messenger rna
WO2021127641A1 (en) 2019-12-20 2021-06-24 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
WO2021142280A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Methods of making tolerogenic dendritic cells
EP4096720A2 (en) 2020-01-30 2022-12-07 ModernaTX, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP7793525B2 (ja) 2020-02-04 2026-01-05 キュアバック エスイー コロナウイルスワクチン
US11969480B2 (en) 2020-02-25 2024-04-30 Translate Bio, Inc. Processes of preparing mRNA-loaded lipid nanoparticles
EP4118207A1 (en) 2020-03-11 2023-01-18 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
CA3172591A1 (en) 2020-03-24 2021-09-30 Douglas Anthony KERR Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
IL296660A (en) 2020-03-24 2022-11-01 Generation Bio Co Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
US12534435B2 (en) 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
IL296781A (en) 2020-03-30 2022-11-01 BioNTech SE Rna compositions targeting claudin-18.2
KR102924173B1 (ko) 2020-04-09 2026-02-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 나노입자 조성물
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
MX2022012683A (es) 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
US11547673B1 (en) 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021226468A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy
WO2021226436A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Optimized nucleotide sequences encoding sars-cov-2 antigens
US12514932B2 (en) 2020-05-14 2026-01-06 Translate Bio, Inc. PEG lipidoid compounds
WO2021231901A1 (en) 2020-05-15 2021-11-18 Translate Bio, Inc. Lipid nanoparticle formulations for mrna delivery
JP2023526422A (ja) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー コロナウイルス抗原組成物及びそれらの使用
EP4153223A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
CN116018405A (zh) 2020-05-29 2023-04-25 旗舰先锋创新Vi有限责任公司 Trem组合物及其相关方法
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
CN116322758A (zh) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
JP2023530974A (ja) 2020-06-15 2023-07-20 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーのためのアデノ随伴ウイルスベクター送達
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
CA3182994A1 (en) 2020-06-30 2022-01-06 Bo YING Lipid compounds and lipid nanoparticle compositions
WO2022006527A1 (en) 2020-07-02 2022-01-06 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
IL299571A (en) 2020-07-08 2023-02-01 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
DK4182297T3 (da) 2020-07-16 2025-12-01 Acuitas Therapeutics Inc Kationiske lipider til brug i lipid-nanopartikler
EP4189098A1 (en) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions of dna molecules, methods of making therefor, and methods of use thereof
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
IL300111A (en) 2020-08-06 2023-03-01 Modernatx Inc The vehicles for the transfer of cargo molecules to the airway epithelium
CA3189878A1 (en) 2020-08-19 2022-02-24 Colin O'BANION Adeno-associated virus vectors for treatment of rett syndrome
CN114073677B (zh) * 2020-08-20 2023-06-09 深圳深信生物科技有限公司 一种脂质纳米颗粒
AU2021328980A1 (en) 2020-08-20 2023-03-09 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
MX2023002439A (es) 2020-09-03 2023-05-09 Flagship Pioneering Innovations Vi Llc Composiciones immunogénicas y usos de las mismas.
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
JP2023544197A (ja) 2020-10-06 2023-10-20 トランスレイト バイオ， インコーポレイテッド 脂質ナノ粒子の改善された方法および製剤
US20220133631A1 (en) 2020-10-12 2022-05-05 Translate Bio, Inc. Process of preparing ice-based lipid nanoparticles
WO2022081544A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
CN116917266A (zh) * 2020-10-14 2023-10-20 乔治梅森研究基金会公司 可离子化脂质及其制造和使用方法
EP4229208A4 (en) * 2020-10-14 2024-10-30 George Mason Research Foundation, Inc. METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF
AU2021373892A1 (en) 2020-11-09 2023-07-06 Translate Bio, Inc. Improved compositions for delivery of codon-optimized mrna
AU2021386737A1 (en) 2020-11-25 2023-07-13 Translate Bio, Inc. Stable liquid lipid nanoparticle formulations
EP4025556A4 (en) * 2020-11-27 2023-08-09 Guangzhou Ribobio Co., Ltd LIPID COMPOUND AND ITS COMPOSITION
WO2022112855A1 (en) * 2020-11-27 2022-06-02 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
EP4256054A1 (en) 2020-12-03 2023-10-11 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
KR20230122081A (ko) * 2020-12-18 2023-08-22 제네반트 사이언시즈 게엠베하 Peg 지질 및 지질 나노입자
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3205827A1 (en) * 2020-12-22 2022-06-30 Cornell University Zwitterionic lipid nanoparticle compositions, and methods of use
KR20230135585A (ko) 2020-12-23 2023-09-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 trem의 조성물 및 이의 용도
JP2024501022A (ja) 2020-12-28 2024-01-10 アークトゥルス セラピューティクス， インコーポレイテッド Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ）
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116981692A (zh) 2021-01-14 2023-10-31 翻译生物公司 递送mRNA编码的抗体的方法和组合物
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
US20240317939A1 (en) * 2021-01-15 2024-09-26 Pfizer Inc. Methods for producing of lipids
EP4087938A2 (en) 2021-01-27 2022-11-16 CureVac AG Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN112961065B (zh) * 2021-02-05 2023-03-14 嘉晨西海(杭州)生物技术有限公司 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
JP7683017B2 (ja) * 2021-02-05 2025-05-26 イモーナ（ハンチョウ）バイオテクノロジー カンパニー リミテッド イオン化可能な脂質分子、その製造方法及び脂質ナノ粒子の製造における応用
CN112961091B (zh) * 2021-02-07 2022-06-17 深圳深信生物科技有限公司 一种氨基脂质化合物及其制备方法和用途
IL305021A (en) 2021-02-08 2023-10-01 Univ Texas Unsaturated Dendrimer Compositions, Related Formulations, and Methods of Using Them
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022204219A1 (en) 2021-03-22 2022-09-29 Recode Therapeutics, Inc. Compositions and methods for targeted delivery to cells
JP2024511437A (ja) 2021-03-23 2024-03-13 リコード セラピューティクス，インク． ポリヌクレオチド組成物、関連製剤、およびその使用方法
JP2024512576A (ja) * 2021-03-24 2024-03-19 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための分岐状尾部脂質化合物及び組成物
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
AU2022249357A1 (en) 2021-04-01 2023-10-12 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
CN117327270A (zh) * 2021-04-08 2024-01-02 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
DK4319803T3 (da) 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
CN115197079A (zh) * 2021-04-08 2022-10-18 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
JP2024515668A (ja) * 2021-04-19 2024-04-10 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａの送達のための改善された組成物
AU2022260111A1 (en) 2021-04-20 2023-11-30 Anjarium Biosciences Ag Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
EP4329884A1 (en) 2021-04-27 2024-03-06 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
AU2022263899B2 (en) * 2021-04-28 2024-08-29 Fujifilm Corporation Compound or salt thereof, lipid particles, and pharmaceutical composition
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
EP4204390A1 (en) 2021-05-24 2023-07-05 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
US20240350640A1 (en) * 2021-06-30 2024-10-24 Jenkem Technology Co., Ltd. (Tianjin) Polyethylene glycol lipid and use thereof
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
EP4362920A1 (en) * 2021-07-01 2024-05-08 Translate Bio, Inc. Compositions for delivery of mrna
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
CN115403761B (zh) * 2021-07-23 2025-04-25 天津键凯科技有限公司 一种多元甘醇修饰的脂质化合物及其制备方法和应用
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023015261A1 (en) 2021-08-04 2023-02-09 Modernatx, Inc. Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN118043466A (zh) 2021-09-03 2024-05-14 葛兰素史克生物有限公司 自扩增信使核糖核酸中核苷酸碱基的取代
EP4395748A1 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
JP2024534523A (ja) 2021-09-21 2024-09-20 スクライブ・セラピューティクス・インコーポレイテッド 操作されたｃａｓｘリプレッサー系
JP2024536406A (ja) 2021-10-08 2024-10-04 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
IL311855A (en) 2021-10-08 2024-05-01 Pfizer Immunogenic lnp compositions and methods thereof
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
AU2022370530A1 (en) 2021-10-18 2024-05-02 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
JP2024539512A (ja) 2021-10-22 2024-10-28 セイル バイオメディシンズ インコーポレイテッド Ｍｒｎａワクチン組成物
EP4423095A1 (en) * 2021-10-26 2024-09-04 AstraZeneca AB Novel lipids for delivery of nucleic acid segments
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
JP2024540170A (ja) 2021-11-01 2024-10-31 モデルナティエックス インコーポレイテッド インテグリンベータ－６をコードするポリヌクレオチド及びその使用方法
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
TW202334080A (zh) 2021-11-08 2023-09-01 美商歐納醫療公司 用於遞送環狀聚核苷酸之脂質奈米粒子組合物
WO2023086893A1 (en) 2021-11-10 2023-05-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
JP2024545584A (ja) 2021-11-12 2024-12-10 モデルナティエックス インコーポレイテッド ペイロード分子を気道上皮に送達するための組成物
CA3238292A1 (en) 2021-11-16 2023-05-25 Alessandra Bartolozzi Novel ionizable lipids and lipid nanoparticles and methods of using the same
CR20240253A (es) 2021-11-18 2024-08-23 Astrazeneca Ab Lípidos novedosos para la administración de segmentos de ácidos nucleicos
EP4436549A1 (en) 2021-11-22 2024-10-02 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
JP2024541467A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー コロナウイルス免疫原組成物及びそれらの使用
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
IL312965A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CA3242406A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Fluorinated cationic lipids for use in lipid nanoparticles
KR20240122872A (ko) 2021-12-16 2024-08-13 아퀴타스 테라퓨틱스 인크. 지질 나노입자에 사용하기 위한 플루오르화 양이온성 지질
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
AU2022413687A1 (en) 2021-12-17 2024-06-27 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
AU2022410694A1 (en) 2021-12-17 2024-07-04 Pfizer Inc. Polynucleotide compositions and uses thereof
EP4452239A1 (en) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
EP4453201A1 (en) 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
JP2025500358A (ja) 2021-12-23 2025-01-09 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 抗膜融合ポリペプチドをコードする環状ポリリボヌクレオチド
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
JP2025502599A (ja) 2021-12-23 2025-01-28 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
IL314191A (en) * 2022-01-17 2024-09-01 St Pharm Co Ltd An ionizable lipid containing an ester bond that breaks down naturally and lipid nanoparticles containing it
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023141624A1 (en) * 2022-01-24 2023-07-27 Verily Life Sciences Llc Ionizable lipids, lipid nanoparticles, and uses thereof
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
CN114409554A (zh) * 2022-01-27 2022-04-29 英维沃生物科技(苏州)有限公司 一种新型阳离子脂质化合物及其组合物和用途
US20250345416A1 (en) 2022-01-27 2025-11-13 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
TW202345863A (zh) 2022-02-09 2023-12-01 美商現代公司 黏膜投與方法及調配物
CA3243905A1 (en) 2022-02-10 2023-08-17 Christiana Care Gene Editing Institute, Inc. METHODS FOR ADMINISTRATING A LIPID NANOPARTICLE FROM A CRISPR-CAS SYSTEM
TW202345864A (zh) 2022-02-18 2023-12-01 美商現代公司 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途
CN119072330A (zh) 2022-03-14 2024-12-03 世代生物公司 异源初免加强疫苗组合物和使用方法
WO2023177904A1 (en) 2022-03-18 2023-09-21 Modernatx, Inc. Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
US20250205167A1 (en) 2022-03-25 2025-06-26 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
US20250250614A1 (en) 2022-04-11 2025-08-07 c/o ModernaTX, Inc. Detection of mrna purity in a mixture
WO2023198084A1 (zh) * 2022-04-12 2023-10-19 厦门赛诺邦格生物科技股份有限公司 一种氮支化非线性聚乙二醇化脂质及其应用
US20250295788A1 (en) * 2022-05-04 2025-09-25 The Trustees Of The University Of Pennsylvania Siloxane-based lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery
CA3257006A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
JP2025516674A (ja) 2022-05-13 2025-05-30 ビオンテック エスエー Ｈｉｖを標的とするｒｎａ組成物
CN119487196A (zh) 2022-05-13 2025-02-18 旗舰创业创新七公司 双链dna组合物及相关方法
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
WO2023225524A1 (en) 2022-05-17 2023-11-23 Modernatx, Inc. Preparation of highly concentrated mrna
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
IL316504A (en) 2022-05-25 2024-12-01 BioNTech SE RNA compositions for the delivery of monkeypox antigens and related methods
JP2025518221A (ja) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア 核酸の送達のための複合体
US20250333767A1 (en) 2022-06-02 2025-10-30 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
EP4536819A1 (en) 2022-06-07 2025-04-16 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
EP4314267A1 (en) 2022-06-07 2024-02-07 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
AU2023283348A1 (en) 2022-06-07 2025-01-09 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
WO2023242817A2 (en) 2022-06-18 2023-12-21 Glaxosmithkline Biologicals Sa Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
EP4544043A1 (en) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
US20260007604A1 (en) 2022-06-23 2026-01-08 Pfizer Inc. USE OF A SPRAY FREEZE-DRYING PROCESS FOR THE LYOPHILIZATION OF A mRNA-ENCAPSULATING LIPID NANOPARTICLES FORMULATION
EP4544051A2 (en) 2022-06-24 2025-04-30 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
JP2025521912A (ja) 2022-07-06 2025-07-10 モレキュラー アクシオム エルエルシー 膵臓癌を治療するための組成物及び方法
US20250360199A1 (en) 2022-07-07 2025-11-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Immunogens and methods for inducing an immune response
CA3261865A1 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
CA3261283A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory Proteins and Associated Methods
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
CN117126071A (zh) * 2022-08-12 2023-11-28 上海蓝鹊生物医药有限公司 含氮链状化合物、其制备方法、包含其的组合物和应用
CN119654141A (zh) 2022-08-18 2025-03-18 苏州艾博生物科技有限公司 脂质纳米颗粒的组合物
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
EP4573200A2 (en) 2022-08-19 2025-06-25 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
US20260069712A1 (en) 2022-08-23 2026-03-12 Modernatx, Inc. Methods for purification of ionizable lipids
CA3264851A1 (en) * 2022-08-26 2024-02-29 Renagade Therapeutics Management Inc. PEGYLATED LIPID COMPOUNDS AND THEIR METHODS OF USE
AU2023334610A1 (en) 2022-08-31 2025-03-13 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
US20250387764A1 (en) 2022-09-15 2025-12-25 Pfizer Inc. Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
WO2024061204A1 (zh) 2022-09-19 2024-03-28 苏州盛迪亚生物医药有限公司 一种制备2-羟乙基氨基己酸酯类化合物方法及其应用
CN120239746A (zh) 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
AU2023347387A1 (en) 2022-09-23 2025-04-10 BioNTech SE Compositions for delivery of liver stage antigens and related methods
AU2023347390A1 (en) 2022-09-23 2025-04-10 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
JP2025532686A (ja) 2022-09-26 2025-10-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスワクチン
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
IL319682A (en) 2022-10-06 2025-05-01 BioNTech SE RNA complexes targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
EP4608441A1 (en) 2022-10-27 2025-09-03 Pfizer Inc. Immunogenic compositions against influenza and rsv
KR20240083166A (ko) * 2022-10-27 2024-06-11 에스티팜 주식회사 폐를 표적장기로 하는 생분해성 지질나노입자 약물 전달 제형 및 이의 활용
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
CN120682120A (zh) * 2022-11-03 2025-09-23 上海环码生物医药有限公司 脂质化合物、脂质纳米颗粒和药物组合物
IL320338A (en) 2022-11-04 2025-06-01 Pfizer Fatty compounds and their uses
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
JP2025537178A (ja) 2022-11-08 2025-11-14 オーナ セラピューティクス， インコーポレイテッド 環状ｒｎａ組成物
TW202434728A (zh) 2022-11-08 2024-09-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸的組成物和方法
JP2025535566A (ja) * 2022-11-08 2025-10-24 サムヤン ホールディングス コーポレイション カチオン性脂質及びその製造方法
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024112652A1 (en) 2022-11-21 2024-05-30 Translate Bio, Inc. Compositions of dry powder formulations of messenger rna and methods of use thereof
IL320873A (en) 2022-12-01 2025-07-01 Generation Bio Co Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them
EP4626444A2 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
CN120615013A (zh) 2022-12-01 2025-09-09 世代生物公司 用于细胞靶向的隐形脂质纳米颗粒组合物
CN120693181A (zh) 2022-12-08 2025-09-23 瑞科德治疗公司 脂质纳米颗粒组合物及其用途
CN120615126A (zh) 2022-12-09 2025-09-09 武田药品工业株式会社 经修饰的免疫调节剂
EP4630049A1 (en) 2022-12-11 2025-10-15 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN115819265A (zh) * 2022-12-13 2023-03-21 广东和境生物科技有限公司 一种含酰胺键脂质的合成方法
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
AU2023394992A1 (en) 2022-12-15 2025-07-31 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
CN116284743A (zh) * 2022-12-16 2023-06-23 辅必成（上海）医药科技有限公司 一种甲氧基聚乙二醇2000双十四烷基乙酰胺的制备方法
CN120456919A (zh) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物
AR131438A1 (es) 2022-12-20 2025-03-19 Sanofi Sa VACUNA DE ARNm DE RINOVIRUS
EP4637717A1 (en) 2022-12-23 2025-10-29 Pfizer Inc. Lipid particle compositions and methods of use thereof
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
WO2024141784A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Broadly protective betacoronavirus vaccines and compositions
WO2024141786A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Multitarget vaccines and therapeutics
CN116396178A (zh) * 2023-01-05 2023-07-07 北京悦康科创医药科技股份有限公司 用于递送核酸的可电离阳离子脂质化合物和组合物及用途
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
EP4648794A2 (en) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
WO2024151811A1 (en) 2023-01-11 2024-07-18 Modernatx, Inc. Personalized cancer vaccines
WO2024154052A1 (en) 2023-01-16 2024-07-25 Pfizer Inc. Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
EP4658636A1 (en) 2023-01-31 2025-12-10 Pfizer Inc. Lipid compounds and uses thereof
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節組合物及相關方法
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
IL322201A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA structures containing modified uracil
WO2024173836A2 (en) 2023-02-17 2024-08-22 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
CN121358494A (zh) 2023-03-15 2026-01-16 旗舰创业创新第六有限责任公司 免疫原性组合物及其用途
KR20250162610A (ko) 2023-03-15 2025-11-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用
AU2024248139A1 (en) 2023-03-29 2025-09-25 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
TW202444914A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 抑制子融合蛋白系統
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2024242151A1 (en) 2023-03-29 2025-09-25 Scribe Therapeutics Inc. Compositions and methods for the targeting of lpa
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
EP4687990A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024211518A1 (en) 2023-04-07 2024-10-10 Astrazeneca Ab Fluidic mixer unit device for nanoparticle production
WO2024210160A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited Conjugation complex
WO2024216128A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
EP4695393A1 (en) 2023-04-12 2026-02-18 Flagship Pioneering Innovations VI, LLC Modified trems, compositions, and related methods thereof
EP4698156A1 (en) 2023-04-17 2026-02-25 Sanofi Pasteur Inc. Reconstitutable dry powder formulations and methods of use thereof
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
EP4701658A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
EP4701657A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
AU2024265158A1 (en) 2023-05-03 2025-11-06 BioNTech SE Optimized csp variants and related methods
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
CN121399470A (zh) 2023-05-03 2026-01-23 马尼福尔德生物技术有限公司 用于高通量蛋白质递送、筛选和检测的方法和组合物
WO2024233387A1 (en) 2023-05-05 2024-11-14 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024236504A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Sequences and methods for delivery of dna and rna
WO2024238700A1 (en) 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024236361A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Compositions and methods for delivery of nucleic acids to cells
EP4713453A1 (en) 2023-05-15 2026-03-25 nChroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
CN116270543B (zh) * 2023-05-19 2023-09-26 清华大学 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
MX2025014990A (es) 2023-06-14 2026-02-03 Pfizer Metodo para estabilizar acido ribonucleico (rna)
US20240423915A1 (en) 2023-06-16 2024-12-26 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticles
CN121646577A (zh) 2023-06-16 2026-03-10 爱康泰生治疗公司 含酰胺的脂质
KR20260025140A (ko) * 2023-06-16 2026-02-23 베이징 지타이 라이프 사이언시스 엘티디 신속하게 대사되는 지질 화합물
US20250025427A1 (en) 2023-06-16 2025-01-23 Acuitas Therapeutics, Inc. Mixed amide ester containing lipids for use in lipid nanoparticles
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
US20250001010A1 (en) 2023-06-30 2025-01-02 Christiana Care Gene Editing Institute, Inc. Nras gene knockout for treatment of cancer
WO2025006385A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel malaria vaccine comprising ama1 and ron2 antigens
US12551451B2 (en) 2023-07-06 2026-02-17 SunVax mRNA Therapeutics Inc. Compositions and methods for delivering molecules
CN121532514A (zh) 2023-07-07 2026-02-13 上海环码生物医药有限公司 用于季节性流感的环状rna疫苗及使用方法
WO2025017476A1 (en) 2023-07-19 2025-01-23 Pfizer Inc. Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024335A2 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
AU2024299365A1 (en) 2023-07-24 2026-01-08 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025023311A1 (ja) 2023-07-25 2025-01-30 国立大学法人大阪大学 ワクチンに使用するための組成物
AU2024299627A1 (en) 2023-07-25 2026-01-22 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
AU2024316307A1 (en) 2023-08-03 2026-02-26 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025036992A1 (en) 2023-08-16 2025-02-20 CureVac SE Rna conjugates
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025051994A1 (en) 2023-09-07 2025-03-13 Coave Therapeutics Ionizable lipid nanoparticles
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025057115A2 (en) 2023-09-15 2025-03-20 Pfizer Inc. Methods and compositions for continuous production of nucleic acids
TW202525266A (zh) 2023-09-18 2025-07-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
KR20250060128A (ko) * 2023-10-24 2025-05-07 주식회사 삼양홀딩스 약물전달용 나노입자의 조성물
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
KR20250064439A (ko) * 2023-11-02 2025-05-09 주식회사 삼양홀딩스 양이온성 지질 및 이의 제조방법
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025106738A1 (en) 2023-11-15 2025-05-22 BioNTech SE Sars-cov-2 immunogenic compositions
TW202539697A (zh) 2023-11-15 2025-10-16 德商拜恩技術股份公司 冠狀病毒疫苗
WO2025106806A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025111526A1 (en) 2023-11-22 2025-05-30 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025114520A1 (en) 2023-12-01 2025-06-05 Coave Therapeutics Ionizable lipid nanoparticles
US12553042B2 (en) 2023-12-01 2026-02-17 Recode Therapeutics, Inc. Method for quantifying an amount of capped messenger RNA
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
TW202532053A (zh) * 2023-12-13 2025-08-16 大陸商上海瑞宏迪醫藥有限公司 用於遞送治療劑的組成物和化合物
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025126019A1 (en) 2023-12-13 2025-06-19 Pfizer Inc. Rna molecules
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025126113A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds
WO2025126118A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
TW202525287A (zh) 2023-12-21 2025-07-01 德商拜恩技術運輸科技有限責任公司 可離子化脂質
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
WO2025134046A1 (en) 2023-12-22 2025-06-26 Pfizer Inc. Methods and vaccine compositions for lyme disease
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
CN117964506A (zh) * 2024-01-29 2024-05-03 中国医学科学院生物医学工程研究所 一种基于新型可电离脂质的脂质纳米粒子及其制备方法与应用
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025166993A1 (zh) * 2024-02-05 2025-08-14 复旦大学 一种新型脂质化合物以及组合物和核酸脂质纳米颗粒制剂及其筛选方法和应用
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025184508A1 (en) 2024-03-01 2025-09-04 Acuitas Therapeutics, Inc. Materials and methods for encapsulating therapeutics in lipid nanoparticles
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025192731A1 (ja) * 2024-03-15 2025-09-18 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
US20260061042A1 (en) 2024-03-26 2026-03-05 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025213016A2 (en) 2024-04-04 2025-10-09 Christiana Care Gene Editing Institute, Inc. Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025226816A1 (en) 2024-04-23 2025-10-30 Christiana Care Gene Editing Institute, Inc. Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025238563A1 (en) 2024-05-17 2025-11-20 Pfizer Inc. Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026015882A1 (en) 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026018213A1 (en) 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026020171A2 (en) 2024-07-19 2026-01-22 Aera Therapeutics, Inc. Chimeric antigen receptor constructs
WO2026030275A1 (en) 2024-08-01 2026-02-05 Pfizer Inc. Rna molecules
WO2026033123A1 (en) 2024-08-08 2026-02-12 Sanofi Pasteur Inc. Lipid nanoparticle formulations for mrna delivery
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
CN120698908A (zh) * 2025-01-23 2025-09-26 上海环码生物医药有限公司 脂质化合物、脂质纳米颗粒和药物组合物

Family Cites Families (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856420A (en) * 1955-12-15 1958-10-14 Minnesota Mining & Mfg Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols
US3340299A (en) 1964-03-27 1967-09-05 Air Reduction Tetrasubstituted ethylene diamines
GB1277947A (en) 1968-08-22 1972-06-14 Armour Ind Chem Co Compositions and method for controlling insect pests
US3729564A (en) 1970-12-16 1973-04-24 Pfizer N-secondary alkyl alkanediamines and derivatives thereof as anti-inflammatory agents
JPS5122416B2 (enExample) * 1972-11-11 1976-07-09
DE2633615C3 (de) 1976-07-27 1981-08-13 Bayer Ag, 5090 Leverkusen Verfahren zum Färben von synthetischen Polyamid-Fasermaterialien
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
JPS56150002A (en) * 1980-04-23 1981-11-20 Nisshin Flour Milling Co Ltd Nonaprenylamine derivative
US4883751A (en) 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
US5858980A (en) 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
JP2651742B2 (ja) * 1990-05-28 1997-09-10 富士写真フイルム株式会社 色素固定要素
JP2588339B2 (ja) 1992-06-02 1997-03-05 花王株式会社 新規ジアミノジエステル及びその製造法
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
CA2227373A1 (en) 1995-07-21 1997-02-06 Promega Biosciences, Inc. Novel amide-based cationic lipids
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
JPH103643A (ja) 1996-06-12 1998-01-06 Fuji Photo Film Co Ltd ディスク状磁気記録媒体
KR20000049089A (ko) 1996-10-11 2000-07-25 인피늄 홀딩스 비.브이. 연료 조성물
CA2217550A1 (en) 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US5756785A (en) 1997-03-21 1998-05-26 Lambent Technologies, Inc. Guerbet betaines
FR2763943B1 (fr) 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
AU751434B2 (en) 1997-12-23 2002-08-15 Inex Pharmaceuticals Corporation Polyamide oligomers
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6986902B1 (en) 1998-04-28 2006-01-17 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity
US6013813A (en) 1998-06-17 2000-01-11 Hansotech Inc Guerbet based sorbitan esters
US6333433B1 (en) 1998-11-09 2001-12-25 Council Of Scientific Industrial Research Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules
AU1830200A (en) 1998-11-25 2000-06-13 Vanderbilt University Cationic liposomes for gene transfer
US5919743A (en) 1998-12-28 1999-07-06 Petroferm Inc. Guerbet branched quaternary compounds in personal care applications
US7112337B2 (en) * 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
JP2001338416A (ja) 2000-05-25 2001-12-07 Sony Corp ディスク状磁気記録媒体
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
JP4111856B2 (ja) 2002-04-12 2008-07-02 昭和電工株式会社 安定化されたアスコルビン酸誘導体
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US6620794B1 (en) 2002-07-08 2003-09-16 Colonial Chemical Inc. Guerbet functionalized phospholipids
CN101291653B (zh) 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
KR101164256B1 (ko) 2003-09-15 2012-07-10 프로티바 바이오쎄라퓨틱스, 인코포레이티드 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도
DE602005018043D1 (de) 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8192718B1 (en) 2005-01-04 2012-06-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8141043B2 (en) 2005-01-11 2012-03-20 Worksoft, Inc. Automated business process testing that spans multiple platforms or applications
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP1912679A4 (en) 2005-06-15 2009-07-29 Massachusetts Inst Technology AMINOUS LIPIDS AND ITS USES
WO2007012191A1 (en) 2005-07-27 2007-02-01 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
US7443760B2 (en) 2005-09-29 2008-10-28 Hynix Semiconductor Inc. Multi-port memory device with serial input/output interface
JP4681425B2 (ja) 2005-11-15 2011-05-11 花王株式会社 毛髪弾性改善剤
GB2433928B (en) 2006-01-07 2009-10-14 Shane Richard Wootton Apparatus for producing material by a chemical reaction
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
EP2695608B1 (en) 2006-10-03 2016-11-23 Arbutus Biopharma Corporation Lipid containing formulations
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
JP2010519203A (ja) 2007-02-16 2010-06-03 メルク・シャープ・エンド・ドーム・コーポレイション 生物活性分子の活性を強化するための組成物及び方法
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
EP2224912B1 (en) 2008-01-02 2016-05-11 TEKMIRA Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CA2711240C (en) 2008-01-02 2021-10-26 Alnylam Pharmaceuticals, Inc. Liver screening method
CA2711236A1 (en) 2008-01-02 2009-07-16 Alnylam Pharmaceuticals, Inc. Screening method for selected amino lipid-containing compositions
CA2710534C (en) 2008-01-31 2018-09-04 Curevac Gmbh Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
US9446995B2 (en) * 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
PL2285350T3 (pl) 2008-06-16 2018-03-30 Pfizer Inc. Sposoby otrzymywania funkcjonalizowanych kopolimerów dwublokowych stanowiących środki kierujące do stosowania przy wytwarzaniu nanocząstek terapeutycznych
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
ES2765240T3 (es) 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP5777519B2 (ja) * 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
US20120009222A1 (en) 2008-10-27 2012-01-12 Massachusetts Institute Of Technology Modulation of the immune response
WO2010054384A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
DK2355851T3 (en) 2008-11-10 2018-06-25 Arbutus Biopharma Corp Newly known lipids and compositions for release of therapeutic agents
CN102231950A (zh) * 2008-11-17 2011-11-02 安龙制药公司 用于核酸递送系统的可释放聚合脂质
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
CA2760776C (en) 2009-05-05 2019-07-09 Alnylam Pharmaceuticals, Inc. Lipid compositions for the delivery of therapeutic agents
CA3045126A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20120264810A1 (en) 2009-09-22 2012-10-18 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
WO2011043913A2 (en) 2009-10-08 2011-04-14 Merck Sharp & Dohme Corp. Novel cationic lipids with short lipid chains for oligonucleotide delivery
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
EP2506879A4 (en) 2009-12-01 2014-03-19 Protiva Biotherapeutics Inc PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2525781A1 (en) 2010-01-22 2012-11-28 Schering Corporation Novel cationic lipids for oligonucleotide delivery
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2011136369A1 (ja) 2010-04-28 2011-11-03 協和発酵キリン株式会社 カチオン性脂質
US9254327B2 (en) 2010-05-10 2016-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8865675B2 (en) 2010-05-12 2014-10-21 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
HRP20221048T1 (hr) 2010-08-31 2022-11-11 Glaxosmithkline Biologicals Sa Mali liposomi za isporuku rna koja kodira imunogen
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2012040184A2 (en) 2010-09-20 2012-03-29 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
CA2811430A1 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Low molecular weight cationic lipids for oligonucleotide delivery
EP3485913A1 (en) 2010-10-21 2019-05-22 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
EP2635265B1 (en) 2010-11-05 2018-04-04 Sirna Therapeutics, Inc. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
BR122022001262B1 (pt) 2010-11-15 2022-09-27 Life Technologies Corporation Compostos de transfecção contendo amina e complexo de transfecção
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013016058A1 (en) * 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20140243391A1 (en) 2011-07-22 2014-08-28 Centre National De La Recherche Scientifique Phospholipid-detergent conjugates and uses thereof
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
ES2897565T3 (es) 2011-10-18 2022-03-01 Dicerna Pharmaceuticals Inc Lípidos catiónicos de amina y uso de los mismos
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
JP6305343B2 (ja) 2011-12-07 2018-04-04 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP3988537A1 (en) 2011-12-07 2022-04-27 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9446132B2 (en) 2012-03-27 2016-09-20 Sima Therapeutics, Inc. Diether based biodegradable cationic lipids for siRNA delivery
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
CN108929880A (zh) 2012-03-27 2018-12-04 库瑞瓦格股份公司 包含5′toputr的人工核酸分子
CN104220599A (zh) 2012-03-27 2014-12-17 库瑞瓦格有限责任公司 人工核酸分子
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
CN105073135A (zh) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 疫苗接种和抑制pd-1途径的组合
KR102205278B1 (ko) 2013-03-14 2021-01-22 다이서나 파마수이티컬, 인크. 음이온성 약제를 제형화하는 방법
US20160030527A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and Methods for Treatment of Stroke
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
MX2016002153A (es) 2013-08-21 2017-03-01 Curevac Ag Composicion y vacuna para tratar cancer de prostata.
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
US9593077B2 (en) 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2015101414A2 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
WO2015123576A2 (en) 2014-02-17 2015-08-20 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10406059B2 (en) 2014-04-21 2019-09-10 The Trustees Of Columbia University In The City Of New York Human movement research, therapeutic, and diagnostic devices, methods, and systems
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
US10309541B2 (en) 2014-05-22 2019-06-04 Flowserve S.R.L. Guide element for a valve actuator and actuator provided with said guide element
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
JP6339884B2 (ja) 2014-07-17 2018-06-06 富士フイルム株式会社 イミダゾール化合物およびそれを含有するリポソーム
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
KR102580696B1 (ko) 2014-12-30 2023-09-19 큐어백 에스이 신규 인공 핵산 분자
CN104876831B (zh) 2015-04-03 2017-05-17 苏州圣诺生物医药技术有限公司 脂质修饰精胺衍生物及利用该衍生物制备的脂质体
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
EP3289083A4 (en) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
AU2016264027A1 (en) 2015-05-15 2017-08-31 Curevac Ag Prime-boost regimens involving administration of at least one mRNA construct
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
CN114085198A (zh) 2015-06-29 2022-02-25 爱康泰生治疗公司 用于递送核酸的脂质和脂质纳米颗粒制剂
EP3331555A1 (en) 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
WO2017025120A1 (en) 2015-08-07 2017-02-16 Curevac Ag Process for the in vivo production of rna in a host cell
WO2017036580A1 (en) 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
WO2017048770A1 (en) 2015-09-15 2017-03-23 Regulus Therapeutics, Inc. Systems, compositions, and methods for formulating nucleic acid compositions
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
EP4582098A3 (en) 2015-11-09 2025-12-24 CureVac SE Optimized nucleic acid molecules
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
SG11201806340YA (en) 2016-02-17 2018-09-27 Curevac Ag Zika virus vaccine
US20170266292A1 (en) 2016-03-21 2017-09-21 The Research Foundation For The State University Of New York Lipidic compound-telodendrimer hybrid nanoparticles and methods of making and uses thereof
SMT202500211T1 (it) 2016-03-30 2025-07-22 Intellia Therapeutics Inc Formulazioni di nanoparticelle lipidiche per componenti crispr/cas
EP4487869A3 (en) 2016-04-22 2025-07-30 CureVac SE Rna encoding a tumor antigen
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
CN109152735B (zh) 2016-05-09 2022-03-11 阿斯利康(瑞典)有限公司 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
IL317855A (en) 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
EP4714454A2 (en) 2016-10-26 2026-03-25 Acuitas Therapeutics Inc. Lipid nanoparticle formulations
US20190274968A1 (en) 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
AU2017374042C1 (en) 2016-12-09 2024-07-11 Acuitas Therapeutics, Inc. Delivery of target specific nucleases
WO2018130584A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
WO2018164674A1 (en) 2017-03-07 2018-09-13 Pleasant Anthem Automated postal delivery notification based on geolocation
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP4613367A1 (en) 2018-09-21 2025-09-10 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
DK4182297T3 (da) 2020-07-16 2025-12-01 Acuitas Therapeutics Inc Kationiske lipider til brug i lipid-nanopartikler

Also Published As

Publication number Publication date
EP3160938B1 (en) 2020-09-16
JP2025111544A (ja) 2025-07-30
PL3766916T3 (pl) 2023-02-27
IL298516A (en) 2023-01-01
IL298516B2 (en) 2025-03-01
AU2024202770A1 (en) 2024-05-16
US20170283367A1 (en) 2017-10-05
CA3179824A1 (en) 2015-12-30
PT3766916T (pt) 2022-11-28
IL316479A (en) 2024-12-01
JP2023055841A (ja) 2023-04-18
US11634379B2 (en) 2023-04-25
WO2015199952A1 (en) 2015-12-30
AU2022200794B2 (en) 2024-02-08
US10723692B2 (en) 2020-07-28
AU2015280499A1 (en) 2017-02-09
IL289934B (en) 2022-12-01
EP3766916A1 (en) 2021-01-20
ES2931832T3 (es) 2023-01-03
EP3766916B1 (en) 2022-09-28
AU2022200794A1 (en) 2022-02-24
EP3160938A1 (en) 2017-05-03
AU2020204111A1 (en) 2020-07-09
CN111454165A (zh) 2020-07-28
IL289934B2 (en) 2023-04-01
JP2022008909A (ja) 2022-01-14
CN111454165B (zh) 2024-01-05
ES2834556T3 (es) 2021-06-17
IL260772B (en) 2020-10-29
CN106795096A (zh) 2017-05-31
CA2953341A1 (en) 2015-12-30
HUE060907T2 (hu) 2023-04-28
US20150376115A1 (en) 2015-12-31
AU2015280499B2 (en) 2020-03-19
US10106490B2 (en) 2018-10-23
IL289934A (en) 2022-03-01
CN106795096B (zh) 2020-05-29
LT3766916T (lt) 2023-01-10
US20210107861A1 (en) 2021-04-15
IL277448A (en) 2020-11-30
JP2019218403A (ja) 2019-12-26
US9738593B2 (en) 2017-08-22
US20170157268A1 (en) 2017-06-08
HRP20221536T1 (hr) 2023-02-17
EP4148083A1 (en) 2023-03-15
JP2017522376A (ja) 2017-08-10
SI3766916T1 (sl) 2023-01-31
JP6594421B2 (ja) 2019-10-23
IL298516B1 (en) 2024-11-01
SMT202200502T1 (it) 2023-01-13
JP7221353B2 (ja) 2023-02-13
IL277448B (en) 2022-02-01
US9737619B2 (en) 2017-08-22
AU2020204111B2 (en) 2021-11-11
IL249718A0 (en) 2017-02-28
US20190270697A1 (en) 2019-09-05
CA2953341C (en) 2023-01-24
US20250034081A1 (en) 2025-01-30
JP6957573B2 (ja) 2021-11-02

Similar Documents

Publication Publication Date Title
AU2022200794B2 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12151996B2 (en) Lipids for lipid nanoparticle delivery of active agents
US20220072155A1 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20160376224A1 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40090394A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40045790B (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40045790A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20250236586A1 (en) Lipids for lipid nanoparticle delivery of active agents